In the present study, we have used a Ba/F3 cell line model to rapidly assess the transforming activity and drug sensitivity of a selected cohort of EGFR variants, and included some that are reported previously 16, 17, 18, 19, 20, 21, 22, 23, 25 and some novel variants from a recently published cohort of Hispanic lung cancer patients 24. This evidence concerns the gene EGFR and lung cancer.